Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384601 | 1.00 | MAPT (0.53) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL19470934 | 0.91 | NQO2 (0.52) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL19937123 | 0.89 | MAPT (0.42) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL31193178 | 0.85 | MAPT (0.43) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL681846 | 0.84 | TDP1 (0.58) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL681084 | 0.84 | MAPT (0.42) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL7691783 | 0.82 | NQO2 (0.54) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL1879471 | 0.80 | ERBB2 (0.72) | ERBB2ALDH1A1KDM4EGAAHSD17B10 | |
| SCHEMBL10562956 | 0.79 | MAPT (0.48) | MAPTERBB2ALDH1A1HPGDKDM4E | |
| SCHEMBL15522442 | 0.79 | KMT2A (0.64) | MAPTERBB2ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108358997-A | A kind of stabilization polypeptide that intracellular that modifying construction of strategy using double sulfosalts is reversible | 北京大学深圳研究生院 | 2018-08-03 | — | — | CN | claimed |
| CN-102584869-B | 2-nuclear magnetic resonance imaging contrast agent taking 2, 3-biquinoxaline as connecting body and preparation method thereof | CHANGCHUN APPLIED CHEMISTRY | 2014-01-08 | — | — | CN | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| EP-4687997-A2 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Sorrento Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250205350-A1 | Antibody-Drug Conjugates and Uses Thereof | VIVASOR, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2025031383-A1 | BIFUNCTIONAL LINKER COMPOUND, ANTIBODY DRUG CONJUGATE, PREPARATION METHOD FOR ANTIBODY DRUG CONJUGATE, AND USE OF ANTIBODY DRUG CONJUGATE | 杭州爱科瑞思生物医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2025021868-A1 | TRAF2 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2025-01-30 | — | — | WO | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| EP-4470560-A1 | TUMOR IMMUNOTHERAPY | Pingshan Translational Medicine Center, Shenzhen Bay Laboratory (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-5360797-A | Bisphosphonic acid derivatives useful as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1994-11-01 | — | — | US | disclosed |
| US-5298498-A | Antiarthritic agents | THE UPJOHN COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0561948-A1 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS. | UPJOHN CO (US) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992014740-A1 | QUINOXALINE PHOSPHONO-AMINO ACIDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992010504-A2 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1992-06-25 | — | — | WO | disclosed |
| US-5118675-A | Therapy for central nervous system disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0389236-A2 | Photopolymerisable composition | Horsell Plc (GB) | 1990-09-26 | — | — | EP | disclosed |
| US-3959100-A | OPACIFIER | SCM CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | MAPT 609/4885ERBB2 1198/4885ALDH1A1 3331/4885 |
| US-20250205350-A1 | Antibody-Drug Conjugates and Uses Thereof | ADCY6, ADCY10, ADCY7 | MAPT 2402/4885ERBB2 560/4885ALDH1A1 591/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | MAPT 609/4885ERBB2 1198/4885ALDH1A1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.